Comparative Pharmacology
Head-to-head clinical analysis: KEFUROX versus KEFZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFUROX versus KEFZOL.
KEFUROX vs KEFZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
750 mg to 1.5 g intramuscularly or intravenously every 8 hours; for severe infections, 1.5 g intravenously every 6 to 8 hours.
1-2 g IV/IM every 8 hours for moderate to severe infections; maximum 12 g/day.
None Documented
None Documented
1.2-1.6 hours in adults with normal renal function (Clcr >80 mL/min); prolonged to 10-20 hours in end-stage renal disease (Clcr <10 mL/min).
1.5-2 hours in adults with normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: minimal (<5%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic